Table 2.

Zika Virus Screening Protocols (NYC Health + Hospitals, Oct. 2016)

Criteria for testing
  1. Pregnant women who

    1. traveled while pregnant to an area with Zika virus transmission OR

    2. had unprotected sex (vaginal, anal, or oral) with a partner who spent time in an area with Zika virus transmission

  2. Persons who develop/developed compatible symptoms during or within 4 weeks of travel to an area with Zika virus transmission

  3. Neonates with suspected or confirmed microcephaly or intercranial calcifications born to women who

    1. traveled while pregnant to an area with Zika virus transmission OR

    2. had unprotected sex (vaginal, anal, or oral) with a partner who spent time in an area with Zika virus transmission

  4. Anyone who developed Guillain-Barré syndrome after spending time in an area with active Zika virus transmission

  5. Other special conditions with epidemiological linkage to a confirmed or probably case of Zika virus infection including

    1. recipient of blood, blood products, or organ transplant OR

    2. suspected transfusion-associated transmission, OR

    3. suspected mosquito-borne transmission, OR

    4. any other unusual clinical manifestation or suspected route of exposure

Laboratory testing, if indicated, can be performed at DOHMH or at a specified commercial laboratory.
    Patient specimens from travel-associated cases of suspected Zika virus infection are sent to the commercial laboratory for testing and do not require the clinician to call DOHMH.
    Clinicians are instructed to call DOHMH for testing in all nontravel-associated cases of suspected Zika virus disease.
  • DOHMH, Department of Health and Mental Hygiene.